Post-vaccination SARS-COV-2 IgG Level: An evaluation study on 2 Area In Indonesia
Corona Virus Disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a global pandemic. Currently there is no effective treatment for this disease, vaccination is one way to deal with this disease. Antibodies that are formed after vaccination are expe...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Indonesian |
| Published: |
Poltekkes Kemenkes Yogyakarta
2024-07-01
|
| Series: | Jurnal Teknologi Laboratorium |
| Subjects: | |
| Online Access: | https://teknolabjournal.com/index.php/Jtl/article/view/447 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Corona Virus Disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a global pandemic. Currently there is no effective treatment for this disease, vaccination is one way to deal with this disease. Antibodies that are formed after vaccination are expected to provide protection for everyone. This study was to determine the levels of IgG antibodies formed after SARS-CoV-2 vaccination. 87 respondents were examined in this study using blood samples. Measurement of antibody levels using the CLIA method. The results obtained show that the average level of antibodies formed is 193.355 BAU/ml. 65 respondents who received 3 doses of vaccine (199.652 BAU/ml) had higher antibody levels than respondents who received two doses of vaccine (175.531 BAU/ml) and 1 dose of vaccine (158.365 BAU/ml). Antibody levels in respondents who were examined between 0-6 months after vaccination (202.827 BAU/ml) had higher levels than respondents with a period of more than six months (186.010 BAU/ml). From the study results, data was obtained that the antibody levels in recipients of three vaccine doses were higher so that they could provide sustainable protection against COVID-19. Therefore, the COVID-19 vaccine booster should give to all people to provide protection against COVID-19. |
|---|---|
| ISSN: | 2338-5634 2580-0191 |